Clinical trials: Nonalcoholic Steatohepatitis
Fatty Liver Disease, Nonalcoholic
Quantitative US for Evaluation of Hepatic Steatosis in MAFLD With UDFF
Ultrasound Derived Fat Fraction (UDFF) Evaluation of Metabolic Related Fatty Liver Disease (MAFLD) in obesity Patients Metabolic fatty liver disease (MAFLD), formerly known as Nonalcoholic Fatty Liver Disease (NAFLD), is the most…
- Trial name
- NCT06097338
- Testing
- bariatric surgery (BS)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Qianfoshan Hospital
Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
A Study in Participants With Non-cirrhotic NASH With Fibrosis
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial. Participants will be in the trial for up to 24 weeks, including a screening period lasting up to 8 weeks, a 12-week treatment period, and…
- Trial name
- COSMOS (NCT05638737)
- Testing
- AZD4831
- Where
- 65 sites in United States, Argentina and 7 more
- Volunteers
- 112 people
- Sponsor
- AstraZeneca
Liver Diseases
Identification of Hepatic Fibrosis Using 4D-MRI
To date, no specific treatment options exist for liver diseases, and there is a large global effort to find drugs that will halt liver disease progression in these patients.Liver fibrosis staging is essential as a…
- Trial name
- 4D-MRI Liver (NCT05385237)
- Testing
- 4D-MRI
- Where
- 2 sites in Switzerland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
NASH - Nonalcoholic Steatohepatitis
Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers
This is a non-randomized, 2-part, open-label, drug-drug interaction (DDI) study to evaluate the effect of concomitant administration of fluconazole or quinidine on the pharmacokinetics and safety of EDP-305 in healthy human…
- Trial name
- NCT03610945
- Testing
- Fluconazole, Quinidine, EDP-305
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
NAFLD, Diabetes Mellitus
Deep Phenotyping of Peripheral Blood Cells and Circulating Factors in Metabolic Diseases
The goal of this cross-sectional observational study is to to perform a thorough characterization of the quantitative and qualitative differences in peripheral blood cells, and circulating factors (proteins, metabolites, lipids…
- Conditions
- NAFLD, Diabetes Mellitus, Obesity
- Trial name
- PERIMED (NCT06396871)
- Testing
- Oral glucose tolerance test, Liver Ultrasound, Fibroscan of the Liver
- Where
- Germany
- Volunteers
- 180 people
- Sponsor
- Technische Universität Dresden
Severe Hypertriglyceridemia (sHTG), Hypertriglyceridemia
A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial to assess the efficacy and safety of weekly subcutaneous DR10624 injection in adult patients with severe hypertriglyceridemia (sHTG).
- Trial name
- NCT07693777
- Testing
- DR10624 Injection
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
NASH, NAFLD
Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis
The purpose of the KETONASH study is to evaluate, in patients with metabolic-associated fatty liver disease (MAFLD) with non-alcoholic steatohepatitis (NASH) and significant liver fibrosis, the effect of a very low-calorie…
- Conditions
- NASH, NAFLD, Obesity, Liver Fibrosis
- Trial name
- KETONASH (NCT06308757)
- Testing
- Very-low-calorie ketogenic diet (VLCKD) with meal replacements, Mediterranean low-calorie diet (LCD)
- Where
- Italy
- Volunteers
- 42 people
- Sponsor
- University of Bologna
Type 2 Diabetes, Coronary Heart Disease
NMR Metabolomics-Based Risk Assessment and Stratified Digital Health Interventions in Middle-Aged Adults (PREMAP)
PREMAP invites residents of the Eloisa region (South Savo, Finland) turning 45, 50, or 55 years of age in 2026 to undergo a blood-based NMR metabolomics risk assessment for five interlinked cardio-renal-metabolic conditions (type…
- Conditions
- Type 2 Diabetes, Coronary Heart Disease, Myocardial Infarction, Cerebrovascular Disease
- Trial name
- PREMAP (NCT07820800)
- Testing
- Digital health interventions
- Where
- Finland
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- University of Eastern Finland
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH), Metabolic Syndrome
ENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study
The ENDOCARE-SCREEN study is a single-center, observational, cross-sectional screening study designed to assess the prevalence, phenotypes, and determinants of metabolic dysfunction-associated steatotic liver disease…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH), Metabolic Syndrome, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- ENDOCARE-SCREE (NCT07336563)
- Where
- Poland
- Volunteers
- 10,000 people
- Sponsor
- Jarosław Drobnik
Nonalcoholic Steatohepatitis
Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis
Nonalcoholic Steatohepatitis (NASH) is a condition with increased amount of fat, inflammation and scarring in the liver. In compensated cirrhosis, the liver is coping with this damage and maintaining its important functions.
- Trial name
- NCT05720663
- Testing
- Standard of care
- Where
- 2 sites in United States
- Volunteers
- 240 people
- Sponsor
- Virginia Commonwealth University
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease
Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to evaluate the efficacy of rosiglitazone alone compared with rosiglitazone plus metformin or rosiglitazone plus losartan in the treatment of biopsy proven nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT00699036
- Testing
- avandia, metformin, losartan
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- Brooke Army Medical Center
Nonalcoholic Steatohepatitis
Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome
This clinical study is designed to evaluate the safety and immune modulatory effects of oral administration of the study drug anti-CD3 monoclonal antibody (MAb) to subjects with the metabolic syndrome.
- Trial name
- NCT01205087
- Testing
- OKT3
- Where
- Israel
- Volunteers
- 36 people
- Sponsor
- Hadassah Medical Organization
Non-Alcoholic Fatty Liver Disease
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)
This extension study will assess the safety and effects of 24 weeks of treatment with ALT-801 in diabetic and non-diabetic subjects with overweight and obesity and non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT05292911
- Testing
- ALT-801
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Altimmune, Inc.
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Effect of Adjustable Intragastric Balloon in Obese Non-alcoholic Fatty Liver Disease
Aims and objectives: The Investigator aimed to evaluate effect of adjustable intra gastric balloon on non-alcoholic fatty liver disease/non alcoholic steatohepatitis (NAFLD/NASH) with or without diabetes mellitus, who have failed…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04182646
- Testing
- Spartz Balloon
- Where
- India
- Volunteers
- 36 people
- Sponsor
- Asian Institute of Gastroenterology, India
NAFLD
Comparison of Two sTRAtegies For the Non-Invasive Diagnosis of advanCed Liver Fibrosis in NAFLD
NAFLD, closely linked to overweight and insulin resistance, has reached 25% prevalence worldwide. Advanced liver fibrosis(ALF) must be accurately diagnosed in NAFLD because it defines a subgroup of patients with impaired…
- Trial name
- TRAFIC (NCT04681573)
- Testing
- blood tests
- Where
- 20 sites in France
- Volunteers
- 1,045 people
- Sponsor
- University Hospital, Angers
Non-Alcoholic Steatohepatitis (NASH)
Evaluating the Efficacy and Safety of Roflumilast in Patients with NASH
Study type :clinical trial Main purpose :esnsure safety and efficacy of Roflumilast to treat patients with Non-Alcoholic Steatohepatitis Background and aim: Non-alcoholic fatty liver disease is the most prevalent chronic liver…
- Trial name
- NCT06677788
- Testing
- Roflumilast 500 Mcg Oral Tablet, Vitamin E capsule
- Where
- Egypt
- Volunteers
- 55 people
- Sponsor
- Tanta University
Non-Alcoholic Fatty Liver Disease
Effect of Indo-Mediterranean Diet on Hepatic Steatosis and Fibrosis in NAFLD Children
NAFLD encompasses the entire spectrum of Fatty liver disease in individuals without significant alcohol consumption, ranging from fatty liver to steatohepatitis to cirrhosis.
- Trial name
- NCT05073588
- Testing
- Indo Mediterranean diet, Calorie restricted diet
- Where
- India
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Institute of Liver and Biliary Sciences, India
Non-alcoholic Fatty Liver Disease
Urinary Metabonomics of Two Major Patterns of NAFLD
NAFLD(non-alcoholic fatty liver disease, NAFLD) is a common liver disease with a high morbidity which seriously influence people's health.
- Trial name
- NCT02077283
- Where
- China
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- ShuGuang Hospital
Steatohepatitis
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.
The purpose of this study is to measure the safety, tolerability, and PK (measurement of drug activity in the body over time) of AZD7503 injected subcutaneously, and compared to placebo, in participants with suspected NASH, a…
- Trial name
- NCT05864391
- Testing
- AZD7503
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Non-Alcoholic Fatty Liver Disease
Berberine and Non-Alcoholic Fatty Liver Disease (NAFLD)
Non-alcoholic fatty liver disease (NAFLD), one of the most common liver dysfunctions, affects about one-fourth of the global adult population and has a significant mortality rate between 6.3% and 33%.NAFLD can lead to other…
- Trial name
- NAFLD (NCT04049396)
- Testing
- Berberine
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- Lida Nejati
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.